Clinical Trials Arena on MSN
IntraBio’s ataxia-telangiectasia drug meets endpoints in pivotal trial
If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.
Please provide your email address to receive an email when new articles are posted on . Areas of the brain in those with stroke were analyzed for lesion activity and functional connectivity. In 54% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results